| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
AstraZeneca PLC$171.61
-6.69 (-3.75%)
A 86Pipeline Score Fair Value Pharma · Commercial
Market Cap
275.20 B
EPS
6.61
P/E Ratio
27.04 $
Value Trade
422.23 M
2.06 %
Week
-4.84 %
1 Month
-9.47 %
3 Month
4.92 %
6 Month
64.22 %
5 Year
368.75 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
3.60 M
52 Week Range
134.90 - 212.71
% held by Insiders
3.44 %
% held by Institutions
62.19 %
Enterprise Value
301.56 B
Total Shares
1.55 B
Short %
0.09 %
Float Shares
1.48 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for AstraZeneca PLC
44Total events
7Upcoming
29Tier-1 (high impact)
2024 – 2026Coverage
Upcoming catalysts 7
TBD
T1NDA Submission
Application for ENHERTU followed by THP under review in U.S. for neoadjuvant treatment
Event history 37
Jul 7, 2026
◆PDUFA DateENHERTURegulatory Filing
PDUFA date set for July 7, 2026
HER2 positive early breast cancer with residual invasive disease after neoadjuvant therapysource ↗
Jul 7, 2026
Jul 1, 2026
▲Partnership / LicenseCorporate
Strategic collaboration between Abbisko and AstraZeneca for lumipodlin + Tagrisso combination trial
non-small cell lung cancersource ↗
Jun 2, 2026
◆PDUFA DateDATROWAYRegulatory Filing
PDUFA date set for DATROWAY sBLA in TNBC
metastatic triple negative breast cancersource ↗
May 22, 2026
▲FDA ApprovalDATROWAYFDA Decision
Datroway approved in U.S. for first-line treatment of metastatic triple negative breast cancer in patients not candidates for PD-1/PD-L1 inhibitors
metastatic triple negative breast cancersource ↗
May 20, 2026
▲IND ClearancelumipodlinIND
IND cleared by NMPA for lumipodlin + Tagrisso combination study
EGFR-mutated PD-L1 positive locally advanced or metastatic NSCLCsource ↗
May 18, 2026
◆PDUFA DateENHERTURegulatory Filing
PDUFA date of May 18, 2026 for neoadjuvant sBLA
HER2 positive stage 2 or stage 3 breast cancer (neoadjuvant)source ↗
May 1, 2026
▲AdCom OutcomeTRUQAPAdvisory Committee
ODAC voted 7-1-1 that TRUQAP plus abiraterone and ADT has favorable benefit-risk profile
PTEN-deficient metastatic hormone-sensitive prostate cancersource ↗
Q2 2026
◆PDUFA DateDATROWAYRegulatory Filing
PDUFA date set for Q2 2026
metastatic triple-negative breast cancer (TNBC)source ↗
Mar 9, 2026
▲FDA ApprovalKoselugoFDA Decision
Koselugo approved in Canada for adult NF1 PN
neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromassource ↗
Mar 9, 2026
▲Priority ReviewENHERTURegulatory Filing
Priority Review granted for sBLA in post-neoadjuvant HER2+ early breast cancer
HER2 positive early breast cancer with residual invasive disease after neoadjuvant therapysource ↗
Feb 20, 2026
▲FDA ApprovalCALQUENCEFDA Decision
FDA approval of CALQUENCE plus venetoclax as first all-oral, fixed-duration combination for 1st-line CLL/SLL
chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)source ↗
Drug Pipeline Intelligence
A86
Pipeline Score $243.1B
Pipeline ValueFair Value
Valuation Signal642
Drugs Scored2.9x
rNPV / MCap Top 99%
Large Pharma (rank 10 of 911)
Percentile RankAstraZeneca PLC earns an A-grade pipeline score (86/100), with $243.2B risk-adjusted pipeline value, led by ZD1839 in Carcinoma (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| savolitinib Small molecule | Papillary Renal Cell Carcinoma | Phase 3 | NCT05043090 | 42% | $21.4B | ACTIVE NOT_RECRUITING | 148 | SLOW | C (56) | Feb 1, 2027 | MODERATE_RISK | May 22, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Koselugo | neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas | Phase 3 | 2026-03-09 | In the KOMET Phase III trial, Koselugo demonstrated a statistically significant objective response rate (ORR) of 20% (n=14/71, 95% CI: 11.2, 30.9) in tumor size reduction by cycle 16, compared to 5% with placebo (n=4/74, p=0.01). Read More | Koselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1 Read More | |
Koselugo | neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas | Phase 3 | 2026-03-09 | In the KOMET Phase III trial, Koselugo demonstrated a statistically significant objective response rate (ORR) of 20% (n=14/71, 95% CI: 11.2, 30.9) in tumor size reduction by cycle 16, compared to 5% with placebo (n=4/74, p=0.01). Read More | Koselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1 Read More | |
Koselugo | neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas | Phase 3 | 2026-03-09 | In the KOMET Phase III trial, Koselugo demonstrated a statistically significant objective response rate (ORR) of 20% (n=14/71, 95% CI: 11.2, 30.9) in tumor size reduction by cycle 16, compared to 5% with placebo (n=4/74, p=0.01). Read More | Koselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AZN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AZN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AZN▼ -3.7%today
Helix Announces Multi-Year Agreement with AstraZeneca to Support Genomic Research for Drug Discovery and Development
Helix has entered a multi-year agreement with AstraZeneca to provide access to its GenoSphere cohorts, which include extensive genomic and clinical data. This collaboration aims to enhance drug discovery and development by leveraging integrated clinico-genomic data. The partnership is expected to accelerate biomedical research and improve the development of targeted therapies.
Read more →AZN▲ +6.1%on this newsshared move
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
Abbisko Therapeutics has partnered with AstraZeneca to conduct a Phase I/II clinical trial for lumipodlin (ABSK043), an oral PD-L1 inhibitor, in combination with TAGRISSO® for treating non-small cell lung cancer (NSCLC). The trial aims to evaluate the safety and efficacy of this novel therapy for patients with EGFR mutations and high PD-L1 expression. The IND application for the study was recently approved by the National Medical Products Administration.
Read more →AZNAstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
AstraZeneca has formed a partnership with YMCA of the USA to tackle disparities in cancer care. This collaboration aims to enhance accessibility and improve health outcomes for communities. The initiative is expected to address critical gaps in healthcare services related to cancer treatment and support.
Read more →AZNLung Cancer Research Foundation and AstraZeneca Announce Open Call for Research Proposals with Focus on Small Cell Lung Cancer
The Lung Cancer Research Foundation and AstraZeneca have announced two research awards aimed at improving treatment outcomes for small cell lung cancer (SCLC). The awards, totaling $750,000, will support innovative strategies and patient advocacy efforts. Submissions for research proposals are open until July 15, 2026, with the goal of advancing understanding and treatment of this challenging cancer.
Read more →AZNแอสตร้าเซนเนก้า จับมือ โรช ไดแอกโนสติกส์ เอเชีย แปซิฟิก เร่งสร้างระบบนิเวศด้านพยาธิวิทยาขั้นสูงสำหรับมะเร็งเต้านมและมะเร็งปอด อย่างยั่งยืน แอสตร้าเซนเนก้า และ โรช ไดแอกโนสติกส์ เอเชีย แปซิฟิก ประกาศลงนามบันทึก ความเข้าใจ เพื่อช่วยยกระดับศักยภาพด้านพยาธิวิทยาดิจิทัล...
AstraZeneca has announced the development of an AI-driven companion diagnostic aimed at improving treatment for HER2-positive breast cancer. This innovative technology is designed to enhance predictive accuracy and patient outcomes. The AI system has demonstrated a 60% predictive accuracy, indicating its potential to significantly impact patient care in oncology.
Read more →AZNDatroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Datroway® has received U.S. approval as the first TROP2 directed antibody drug conjugate. It is intended for first-line treatment of patients with metastatic triple negative breast cancer who are not eligible for PD-1/PD-L1 inhibitors. This approval marks a significant advancement in treatment options for this patient population.
Read more →AZN아스트라제네카, 로슈진단 아시아태평양과 함께 유방암 및 폐암 첨단 병리학의 지속 가능한 생태계 가속화 지원 아스트라제네카(AstraZeneca)와 로슈진단 아시아태평양(Roche Diagnostics Asia Pacific)이 아시아 9개 국가의 디지털 병리 역량 강화 및 암 치료 수준 향상을 위한 3년 업무협약(MOU)를 체결했다고 5월 18일 발표했다. 이는 아시아...
AstraZeneca and Roche Diagnostics Asia Pacific have signed a three-year memorandum of understanding to enhance AI-driven diagnostic capabilities. This partnership aims to improve patient outcomes by integrating advanced computational pathology and AI technologies. The collaboration focuses on developing innovative diagnostic solutions for cancer treatment, particularly targeting HER2 and TROP2 biomarkers.
Read more →AZNस्तन तथा फेफड़ों के कैंसर में एडवांस पैथोलॉजी के लिए एक स्थायी इकोसिस्टम को गति देने में सहायता करने के लिए AstraZeneca ने Roche Diagnostics Asia Pacific के साथ सहयोग किया AstraZeneca और Roche Diagnostics Asia Pacific ने आज नौ एशियाई बाजारों में डिजिटल पैथोलॉजी क्षमताओं को आगे बढ़ाने और कैंसर देखभाल को बेहतर बनाने में...
AstraZeneca has partnered with Roche Diagnostics Asia Pacific to enhance digital pathology capabilities for cancer diagnostics. This collaboration aims to leverage AI technology to improve patient outcomes and diagnostic accuracy. The initiative is expected to significantly benefit the healthcare landscape in Asia Pacific, particularly in the management of cancer treatments.
Read more →AZNAstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer AstraZeneca and Roche Diagnostics Asia Pacific today announced a three-year Memorandum of Understanding to help advance digital pathology...
AstraZeneca and Roche Diagnostics Asia Pacific have entered a three-year Memorandum of Understanding to enhance digital pathology capabilities across nine Asian markets. This collaboration aims to improve biomarker testing for breast and lung cancer through AI-powered solutions and educational initiatives. The partnership addresses significant gaps in diagnostic processes and aims to standardize and improve cancer care.
Read more →AZNTRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
The FDA's Oncologic Drugs Advisory Committee has recommended AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer. This recommendation is based on favorable results from the CAPItello-281 Phase III trial, which demonstrated a significant reduction in disease progression. The treatment addresses a critical need for patients with limited options and is the first targeted therapy for this cancer subtype.
Read more →AZNKoselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1
Koselugo (selumetinib) has been approved in Canada for adults with neurofibromatosis type 1 (NF1) suffering from symptomatic, inoperable plexiform neurofibromas. This approval follows positive results from the KOMET Phase III trial, which showed a 20% objective response rate in tumor size reduction. Experts highlight the significance of this treatment option for patients who previously had limited therapeutic choices.
Read more →AZNENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
AstraZeneca and Daiichi Sankyo's ENHERTU has received Priority Review from the FDA for treating HER2 positive early breast cancer patients with residual disease after neoadjuvant therapy. The decision follows promising results from the DESTINY-Breast05 trial, which demonstrated a significant reduction in disease recurrence. The FDA's target action date for this application is July 7, 2026.
Read more →AZNSECURITIES AND EXCHANGE COMMISSION
AstraZeneca PLC has filed a report with the SEC for February 2026, according to the requirements set forth by the Securities Exchange Act of 1934. The filing includes details about the registrant’s annual financial report and compliance with various regulatory requirements. This follows standard practice for foreign issuers under SEC regulations.
Read more →AZNCALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
AstraZeneca's CALQUENCE in combination with venetoclax has received FDA approval as the first all-oral, fixed-duration treatment for chronic lymphocytic leukemia (CLL) in adults. This regimen, based on positive AMPLIFY Phase III trial results, offers a highly effective and well-tolerated option for patients. The treatment showed a 77% progression-free rate at three years, significantly outperforming standard chemotherapy. However, it carries risks of serious infections and other adverse effects.
Read more →AZNPositive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
The Phase III KALOS and LOGOS trials demonstrated that AstraZeneca's BREZTRI significantly improved lung function in patients with uncontrolled asthma compared to standard therapies. The results, published in The Lancet Respiratory Medicine, indicate that BREZTRI also reduced the rate of severe asthma exacerbations. The therapy combines an inhaled corticosteroid, a long-acting beta-agonist, and a long-acting muscarinic antagonist.
Read more →AZNAstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
AstraZeneca has awarded $3.4 million through its ACT on Health Equity initiative to support nonprofit organizations in the US. This funding will enhance healthcare access and address social barriers faced by underserved communities. The initiative has now contributed over $18 million to various health equity programs, focusing on nutrition and lung health among other areas.
Read more →AZNDATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
AstraZeneca and Daiichi Sankyo's DATROWAY (datopotamab deruxtecan-dlnk) has received Priority Review from the FDA for treating metastatic triple-negative breast cancer (TNBC) in patients not eligible for immunotherapy. This designation highlights the drug's potential to significantly improve overall survival compared to existing chemotherapy options. The FDA's decision is expected by the second quarter of 2026.
Read more →AZNDATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
Daiichi Sankyo and AstraZeneca's DATROWAY has received Priority Review from the FDA for treating metastatic triple negative breast cancer (TNBC) patients who cannot undergo immunotherapy. The application is based on promising results from the TROPION-Breast02 trial, showing improved overall survival and reduced disease progression compared to chemotherapy. The FDA's decision is expected by June 2, 2026.
Read more →AZNENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
The European Medicines Agency has validated the Type II Variation application for ENHERTU in combination with pertuzumab as a first-line treatment for HER2 positive metastatic breast cancer. This validation initiates the EMA's scientific review process, following promising results from the DESTINY-Breast09 phase 3 trial. The treatment aims to improve outcomes for patients who have had limited options for over a decade.
Read more →AZNTROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
The TROPION-Lung17 Phase 3 trial has commenced, evaluating DATROWAY in patients with advanced nonsquamous NSCLC. This trial aims to compare DATROWAY to docetaxel in TROP2 NMR positive patients previously treated with immunotherapy and platinum-based chemotherapy. The study is significant as it is the first to prospectively enroll patients based on a TROP2 biomarker, potentially improving treatment outcomes.
Read more →AZNDESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
The DESTINY-Endometrial02 Phase 3 trial has commenced, evaluating ENHERTU as an adjuvant therapy for patients with HER2 expressing endometrial cancer. This trial aims to compare ENHERTU with standard chemotherapy treatments. The study is a collaboration involving multiple organizations and seeks to address the lack of approved HER2 directed therapies in this setting. The trial will enroll around 710 patients across various continents.
Read more →AZNENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
ENHERTU (trastuzumab deruxtecan) has been awarded Breakthrough Therapy Designation by the FDA for treating adult patients with HER2 positive early breast cancer who have residual disease after neoadjuvant therapy. This designation is based on promising results from the DESTINY-Breast05 phase 3 trial, which demonstrated ENHERTU's potential to improve disease-free survival. The drug has now received a total of ten BTDs, highlighting its significant role in breast cancer treatment.
Read more →AZNNo. 2723534 THE COMPANIES ACT 2006 PUBLIC COMPANY LIMITED BY SHARES ARTICLES OF ASSOCIATION OF ASTRAZENECA PLC Incorporated 17 June 1992 Registered Office: 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2
AstraZeneca PLC has published its Articles of Association as part of the compliance with the Companies Act 2006. The document outlines the company's capital structure, rights attached to shares, and governance procedures, including details for general meetings and share transfers. This publication represents a formal update but does not indicate any immediate changes to shareholders' rights or company operations.
Read more →AZNEARLY CHRONIC KIDNEY DISEASE (CKD) INTERVENTION COULD SAVE AUSTRALIA $1 BILLION A YEAR[1] New modelling highlights the potential societal, economic and environmental benefits of early chronic kidney disease (CKD) intervention which could...
AstraZeneca's IMPACT CKD modelling indicates that early intervention in chronic kidney disease (CKD) could save Australia $25.2 billion over 25 years. The model predicts a significant reduction in dialysis demand and improved health outcomes, including decreased cardiovascular events and mortality rates. Additionally, early action could enhance workforce participation and deliver environmental benefits.
Read more →AZNGet To Know Severe Asthma: The Chronic, Life-Threatening Condition Affecting 7-11% Adults In Asian Countries Asthma is well-known as a common respiratory condition. But did you know that there exists a life-threatening type of the condition called severe...
Severe asthma, affecting 7-11% of adults in Asian countries, requires specialized treatment due to its life-threatening nature. Early diagnosis is crucial for effective management, and dedicated clinics offer multidisciplinary care. Symptoms can be unpredictable and challenging to control, necessitating tailored treatment plans, including biologics. Patients are encouraged to monitor their condition closely.
Read more →AZNConsulta Pública avalia incorporação de nova opção de tratamento no SUS para pacientes com HPN, doença ultra rara e grave AstraZeneca – A Hemoglobinúria Paroxística Noturna (HPN) é um dos cerca de 7 mil tipos de doenças raras existentes no mundo4, e sua gravidade...
AstraZeneca's new treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) has been approved by ANVISA. This treatment enhances patient quality of life by reducing fatigue and the risk of thrombosis while requiring fewer infusions. A public consultation is currently open to evaluate its incorporation into the Unified Health System (SUS) until January 15, 2024.
Read more →AZNKoselugo now available in Malaysia for paediatric patients with symptomatic neurofibromatosis type 1 (NF1) plexiform neurofibromas AstraZeneca's Koselugo (selumetinib) is now available in Malaysia as a monotherapy for the treatment of paediatric patients three years of age and...
AstraZeneca's Koselugo (selumetinib) has been approved in Malaysia for pediatric patients aged three and older with symptomatic neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas. This approval aims to address the significant unmet medical needs of NF1 patients, providing them with a much-needed treatment option. The drug has shown promising results in clinical trials, with a confirmed partial response rate of 70%.
Read more →Competitive Position
How AZN ranks across every disease it competes inCompetitive Position is a premium feature
See how AZN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial